Cargando…

Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents

In the present work, three hydroxyxanthones were synthesized in 11.15–33.42% yield from 2,6-dihydroxybenzoic acid as the starting material. The chemical structures of prepared hydroxyxanthones have been elucidated by using spectroscopic techniques. Afterward, the hydroxyxanthones were evaluated as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatmasari, Nela, Kurniawan, Yehezkiel Steven, Jumina, Jumina, Anwar, Chairil, Priastomo, Yoga, Pranowo, Harno Dwi, Zulkarnain, Abdul Karim, Sholikhah, Eti Nurwening
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795354/
https://www.ncbi.nlm.nih.gov/pubmed/35087149
http://dx.doi.org/10.1038/s41598-022-05573-5
_version_ 1784641048681644032
author Fatmasari, Nela
Kurniawan, Yehezkiel Steven
Jumina, Jumina
Anwar, Chairil
Priastomo, Yoga
Pranowo, Harno Dwi
Zulkarnain, Abdul Karim
Sholikhah, Eti Nurwening
author_facet Fatmasari, Nela
Kurniawan, Yehezkiel Steven
Jumina, Jumina
Anwar, Chairil
Priastomo, Yoga
Pranowo, Harno Dwi
Zulkarnain, Abdul Karim
Sholikhah, Eti Nurwening
author_sort Fatmasari, Nela
collection PubMed
description In the present work, three hydroxyxanthones were synthesized in 11.15–33.42% yield from 2,6-dihydroxybenzoic acid as the starting material. The chemical structures of prepared hydroxyxanthones have been elucidated by using spectroscopic techniques. Afterward, the hydroxyxanthones were evaluated as antioxidant agents through radical scavenging assay; and anticancer agents through in vitro assays against WiDr, MCF-7, and HeLa cancer cell lines. Hydroxyxanthone 3b was categorized as a strong antioxidant agent (IC(50) = 349 ± 68 µM), while the other compounds were categorized as moderate antioxidant agents (IC(50) > 500 µM). On the other hand, hydroxyxanthone 3a exhibited the highest anticancer activity (IC(50) = 184 ± 15 µM) and the highest selectivity (SI = 18.42) against MCF-7 cancer cells. From the molecular docking study, it was found that hydroxyxanthone 3a interacted with the active sites of Topoisomerase II protein through Hydrogen bonding with DG13 and π–π stacking interactions with DA12 and DC8. These findings revealed that hydroxyxanthones are potential candidates to be developed as antioxidant and anticancer agents in the future.
format Online
Article
Text
id pubmed-8795354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87953542022-01-28 Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents Fatmasari, Nela Kurniawan, Yehezkiel Steven Jumina, Jumina Anwar, Chairil Priastomo, Yoga Pranowo, Harno Dwi Zulkarnain, Abdul Karim Sholikhah, Eti Nurwening Sci Rep Article In the present work, three hydroxyxanthones were synthesized in 11.15–33.42% yield from 2,6-dihydroxybenzoic acid as the starting material. The chemical structures of prepared hydroxyxanthones have been elucidated by using spectroscopic techniques. Afterward, the hydroxyxanthones were evaluated as antioxidant agents through radical scavenging assay; and anticancer agents through in vitro assays against WiDr, MCF-7, and HeLa cancer cell lines. Hydroxyxanthone 3b was categorized as a strong antioxidant agent (IC(50) = 349 ± 68 µM), while the other compounds were categorized as moderate antioxidant agents (IC(50) > 500 µM). On the other hand, hydroxyxanthone 3a exhibited the highest anticancer activity (IC(50) = 184 ± 15 µM) and the highest selectivity (SI = 18.42) against MCF-7 cancer cells. From the molecular docking study, it was found that hydroxyxanthone 3a interacted with the active sites of Topoisomerase II protein through Hydrogen bonding with DG13 and π–π stacking interactions with DA12 and DC8. These findings revealed that hydroxyxanthones are potential candidates to be developed as antioxidant and anticancer agents in the future. Nature Publishing Group UK 2022-01-27 /pmc/articles/PMC8795354/ /pubmed/35087149 http://dx.doi.org/10.1038/s41598-022-05573-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fatmasari, Nela
Kurniawan, Yehezkiel Steven
Jumina, Jumina
Anwar, Chairil
Priastomo, Yoga
Pranowo, Harno Dwi
Zulkarnain, Abdul Karim
Sholikhah, Eti Nurwening
Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
title Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
title_full Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
title_fullStr Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
title_full_unstemmed Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
title_short Synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
title_sort synthesis and in vitro assay of hydroxyxanthones as antioxidant and anticancer agents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795354/
https://www.ncbi.nlm.nih.gov/pubmed/35087149
http://dx.doi.org/10.1038/s41598-022-05573-5
work_keys_str_mv AT fatmasarinela synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT kurniawanyehezkielsteven synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT juminajumina synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT anwarchairil synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT priastomoyoga synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT pranowoharnodwi synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT zulkarnainabdulkarim synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents
AT sholikhahetinurwening synthesisandinvitroassayofhydroxyxanthonesasantioxidantandanticanceragents